MedCrypt and QuiO said earlier this month that the companies are partnering to integrate MedCrypt’s data security software into QuiO’s Smartinjector devices. According to the agreement, MedCrypt will provide software security for QuiO’s Si One pen for specialty drugs and the Si Pen for diabetes patients. The companies plan to integrate the devices with software […]
Featured
How virtual and mixed reality are changing drug delivery and device design
Kai Worrell believes that virtual and mixed reality may change the way companies design medical devices, and he’s putting that idea into practice. “We think it’s going to transform the way we do feasibility testing and cognitive walk-through simulations,” he said. “We think it’s going to help us understand the cognition of our users, clinical […]
Insulet touts Omnipod Horizon hybrid closed-loop system in patients with T1D
Insulet (NSDQ:PODD) touted data today from the 1st feasibility study of its Omnipod Horizon hybrid closed-loop system in patients with Type 1 diabetes. Data from the study showed that the Omnipod automated glucose control algorithm performed well, with minimal hypoglycemia, and that it was safe. The Billerica, Mass.-based company enrolled 24 patients with Type 1 diabetes […]
Windtree touts preclinical data from influenza study for aerosolized surfactant
Windtree Therapeutics (NSDQ:WINT) said today that a preclinical influenza study demonstrated that its aerosolized KL4 surfactant reduced lung inflammation and improved overall survival in ferrets. In the preclinical study, researchers compared Windtree’s aerosolized KL4 surfactant with a daily oral dose of oseltamivir, an antiviral, and placebo controls. Following exposure to the influenza virus, investigators evaluated […]
Azaya Therapeutics bought by Cytori, nanoparticle program launched
Cytori Therapeutics (NSDQ:CYTX) said yesterday that it completed its acquisition of San Antonio-based Azaya Therapeutics and its nanoparticle cancer drugs. In late January, San Diego-based Cytori said it planned to buy Azaya in a stock deal, offering Azaya shareholders $2 million in CTYX stock. Cytori also said that it paid $2 million upfront for costs associated […]
Clearside enrolls first patient in phase III trial of Zuprata combination therapy
Clearside Biomedical (NSDQ:CLSD) said today that it enrolled the 1st patient in a phase III trial evaluating Zuprata, its suspension formulation of triamcinolone acetonide, in combination with Eylea, intravitreal aflibercept, for the treatment of macular edema associated with retinal vein occlusion. The trial is slated to enroll 460 patients with retinal vein occulsion to assess […]
JDRF backs GluSense with $2m grant
GluSense said yesterday that it received a $2 million grant from the Juvenile Diabetes Research Foundation’s T1D fund for the company’s injectable glucose sensor. Israel-based GluSense, part of Rainbow Medical, is developing the Glyde continuous glucose monitor for patients with Type I diabetes. The device is injected under the skin and lasts for 1 year, […]
How Sanofi blew its chance with Actelion
Days before entering into exclusive takeover negotiations with Johnson & Johnson (NYSE:JNJ), Actelion (VTX:ATLN) was reportedly fielding an offer from Sanofi (NYSE:SNY). But the Swiss biotech eventually agreed to go with J&J’s $30 billion bid in an all-cash deal at the end of January. Actelion accepted the U.S. healthcare giant’s offer because it provided more certainty, Reuters reported today. The prospectus […]
Update: Insulet opens manufacturing facility in Acton, Mass.
Insulet (NSDQ:PODD) said yesterday that it acquired a manufacturing facility in Acton, Mass. The Billerica, Mass.-based company said that its new facility will allow Insulet to more efficiently manufacture its OmniPod system compared to 4 of the company’s manufacturing lines at its contract manufacturer in China. The company anticipates the new facility will add hundreds of jobs in Massachusetts […]
Anika beats Q4 earnings, revenue estimates
Shares in Anika Therapeutics (NSDQ:ANIK) fell today, even though the orthopedic medicines company beat expectations on Wall Street with its 4th quarter results. The Bedford, Mass.-based company posted profits of $8.1 million, or 54¢ per share, on sales of $28.7 million for the 3 months ended Dec. 31, for bottom-line loss of -26% on sales loss of -7% compared with […]